MWG Enterprises, LLC v. ETS Wound Care, LLC

UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF MISSOURI

EASTERN DIVISION

MWG ENTERPRISES, LLC, )

)

Plaintiff, )

)

v. ) Cause No. 4:19-cv-00424-SEP

)

ETS WOUND CARE, LLC, et al., )

)

Defendants. )

MEMORANDUM AND ORDER

Before the Court are Defendants’ Motion for Summary Judgment on all Counts Raised by

Plaintiff and Counts I and III of Defendants’ Amended Counterclaims, Doc. [63], and Plaintiff’s

Motion for Leave to File a Sur Reply, Doc. [82]. For the reasons set forth below, the Motion for

Summary Judgment is granted in part and the Motion for Leave to File a Sur Reply is denied.

FACTUAL BACKGROUND1

This lawsuit arises out of a contract between Plaintiff MWG Enterprises, LLC, d/b/a Atlas

Health Services, LLC, and Defendants ETS Wound Care, LLC, and Kimberly Day2 relating to

Mirragen, a medical device made of bioabsorbable borate-based glass fibers and particles, which enable

it to absorb fluid from wound sites and facilitate healing. Docs. [80] ¶ 1, [64] at 3. ETS designs and

manufactures Mirragen. Doc. [64] at 3. MWG is a distributor. Id.

I. The Distribution Agreement

In 2017, ETS and MWG established a Mirragen distributorship arrangement. On June 12,

2017, ETS and MWG executed a Non-Disclosure Agreement (NDA), Docs. [1] ¶ 9, [15] ¶ 9, and on

July 1, 2017, the parties executed a Distribution Agreement (Agreement), effective on July 20, 2017,

which gave MWG the exclusive right to sell Mirragen in six states and to the entire federal government.

Docs. [80] ¶¶ 1, 3, [64-1] ¶ 1.1. In consideration of its exclusive dealing right, MWG agreed to make

an “initial minimum purchase order” of Mirragen within five days of the Agreement’s execution or a

1 Except as otherwise noted, the facts in this section are not subject to genuine dispute.

2 Donnie Buck was substituted for former Defendant Ted Day, Doc. [48], after Mr. Day passed away on

September 14, 2020, Doc. [47-1]. On February 4, 2022, Kimberly Day, Ted Day’s widow, was substituted for

Donnie Buck. Doc. [114].

contractual “Kickoff meeting,” whichever occurred later. Docs. [1] ¶ 18, [15] ¶ 18.3 MWG also

promised to use “best efforts to promote, demonstrate, stimulate interest in, solicit orders for and

sell” Mirragen in an “end-user environment.” Doc. [64-1] ¶ 2.1. MWG promised to keep records,

make disclosure to ETS regarding product distribution, and refrain from selling Mirragen to persons

or entities that were “not hospitals or appropriate medical facilities.” Id. ¶¶ 3.5, 8.7, 2.3. The

Agreement also authorized either party to terminate the Agreement without providing an opportunity

to cure before completion of its contractual term if the other party committed a material, incurable

breach. Id. ¶ 8.4.

II. The July 13, 2018, Termination Letter

Toward the end of the Agreement’s first one-year term, the relationship between ETS and

MWG soured. On July 13, 2018, ETS sent MWG a letter purporting to terminate the Agreement on

July 20, 2018. Docs. [80] ¶ 15, [64-5] at 1. The Termination Letter alleged several breaches of the

terms of the Agreement. Specifically, it charged that:

(1) MWG had breached its obligation to use its “best efforts” when it was “unable to articulate

the efforts made to solicit interest in the products in the territories” and represented only

that it was “in ‘active communication’ with accounts but could not describe if such

communications” merely solicited opportunities to demonstrate Mirragen. Doc. [64-5] at

2.

(2) MWG had failed to account for product sales, “support[ing] [ETS’s] belief that significant

product has been warehoused or provided to non-customers,” in violation of the

Agreement. Id. ETS also asserted that it believed MWG was illicitly selling Mirragen to

sub-distributors. Id. (citing Doc. [64-1] ¶¶ 2.1, 2.11, 15.4).

(3) MWG had breached its duty of good faith and fair dealing by showing a “lack of diligence

and slacking off and a willful rendering of imperfect performance,” and by

“warehous[ing]” Mirragen and entering into sales with “non-customers.” Id. at 3 (citing

Doc. [64-1] ¶ 2.1).

(4) Because MWG had warehoused product and sold it to non-customers, it had failed to

satisfy the Sales Metrics for the territories. Id. (citing Doc. [64-1] ¶ 7.2).

3 The parties do not dispute that MWG satisfied the “initial minimum purchase order” obligation. Docs. [15]

¶ 31, [31] ¶ 35.

III. July 20, 2018, to Present Lawsuit

After the Termination Letter’s effective date passed and attempts to renegotiate failed, Docs.

[64] at 4, [64-4] at 295:11-15, ETS entered into contracts with alternative distributors to sell Mirragen

in MWG’s exclusive territories while MWG continued to sell Mirragen, Docs. [64] at 4-5, [64-6] ¶ 2.

On March 8, 2019, MWG filed suit against ETS and brought the following claims:

Count I: Declaratory Judgment

Count II: Breach of Contract (Distribution Agreement)

Count III: Breach of Contract (NDA)

Count IV: Recoupment

Count V: Theft of Trade Secrets under Federal Law

Count VI: Theft of Trade Secrets under State Law

Count VII: Tortious Interference

Doc. [1] at 15-26. In Count I, MWG seeks a judicial declaration that the Agreement and NDA

remained in full force and effect since execution. Id. ¶ 75. Count II asserts a breach of contract claim

under the Agreement under the theories that ETS (i) wrongfully terminated the Agreement, (ii) illicitly

granted other distributors the right to sell Mirragen in the exclusive territories, (iii) impermissibly used

MWG’s “customer list,” and (iv) failed to act in good faith. Docs. [1] ¶¶ 79, 82-83, 85, [63] ¶ 1.b. In

Counts III, V, and VI, MWG alleges that ETS breached the NDA and violated both state and federal

trade secrets law by using both: (i) research produced by MWG and the U.S. Department of Defense

(DOD), and (ii) MWG’s “customer list.” Docs. [1] ¶¶ 99-109, 123-42, 144-48, [63] ¶¶ 1.c, 1.e-f. In

Count IV, MWG brings a recoupment claim to recover its financial investment in the Mirragen it

purchased. Docs. [1] ¶ 115-121, [63] ¶ 1.d. And Count VII claims that ETS tortiously interfered in

MWG’s business relationships with its present and potential customers when ETS communicated to

those customers that MWG was no longer an authorized Mirragen distributor. Docs. [1] ¶¶ 152-64,

[63] ¶ 1.g.

ETS filed its Answer, Doc. [15], on April 9, 2019, as well as an Amended Counterclaim and

Affirmative Defenses on August 7, 2019. Doc. [31]. In the Amended Counterclaim, ETS alleges the

following:

Count I: Breach of Contract (Distribution Agreement)

Count II: Tortious Interference

Count III: Declaratory Relief

Count IV: Injunctive Relief

Docs. [31] at 7-25, [63] ¶ 2.a-d.

On March 12, 2021, ETS filed the instant Motion seeking summary judgment on the entire

Complaint and Counterclaim Count III, as well as partial summary judgment on Counterclaim Count

I. Doc. [63] ¶¶ 6-12. ETS argues that there is no genuine dispute of material fact that MWG incurably

and materially breached the Distribution Agreement when it (i) failed to use “best efforts” to sell

Mirragen, (ii) failed to maintain proper records and provide them to ETS, (iii) intentionally provided

ETS with false sales information, and (iv) sold Mirragen to persons and entities that were “not

hospitals or appropriate medical facilities.” Id. ¶¶ 4, 5. Therefore, ETS claims that it is entitled to

summary judgment on Counterclaim Count I and III, id. ¶ 6, as well as Complaint Count I, id. ¶ 4.

Because, in its view, the Agreement was validly terminated, ETS also claims judgment as a

matter of law on MWG’s other claims that depend upon the vitality of the Agreement after July 20,

2018. Specifically, ETS argues that it is entitled to summary judgment on Complaint Count II

concerning ETS’s allegedly wrongful engagement of alternative distributors in MWG’s territory and

the purported termination of the Agreement. Id. ¶¶ 6, 7. ETS also claims that Complaint Count VII

for ETS’s tortious interference with MWG’s business relationships must fail as a matter of law,

because MWG no longer had a right to distribute Mirragen. Id. ¶ 7.

Separately, ETS maintains that summary judgment is proper on Complaint Counts II, III, V,

and VI for ETS’s alleged use of MWG’s “customer list” and DOD research because there is no

evidence that ETS disclosed or misused the list and, even if it had, it obtained no economic benefit.

Id. ¶ 9. ETS states that summary judgment on Complaint Count IV is appropriate because recoupment

is not an affirmative cause of action under Missouri law in these circumstances. Id. ¶ 11. Finally, and

independent of any cause of action, ETS claims it is entitled to judgment as a matter of law that any

damages owed to MWG are contractually restricted to the price MWG paid for its purchased Mirragen.

Id. ¶ 12.

LEGAL STANDARD

Under Federal Rule of Civil Procedure 56, either party may move for summary judgment.

“The court shall grant summary judgment if the movant shows that there is no genuine dispute as to

any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a).

The movant “bears the initial responsibility of informing the district court of the basis for its motion”

and must identify “those portions of [the record] . . . which it believes demonstrates the absence of a

genuine issue of material fact.” Celotex Corp. v. Catrett, 477 U.S. 317, 323 (1986). If the movant meets

this burden, “the burden shifts to the nonmovant to submit evidentiary materials that ‘designate

specific facts showing that there is a genuine issue for trial.’” Miner v. Schrieber, 2020 WL 3605619, at

*1 (E.D. Mo. July 2, 2020) (quoting Celotex, 447 U.S. at 324). An issue of fact is genuine when “a

reasonable jury could return a verdict for the nonmoving party.” Anderson v. Liberty Lobby, Inc., 477

U.S. 242, 248 (1986). “In ruling on a summary judgment motion, a court must view the facts in the

light most favorable to the non-moving party.” Leonetti’s Frozen Food, Inc. v. Re Mktg., Inc., 887 F.3d

438, 442 (8th Cir. 2018) (citation omitted). In reaching its decision, the Court should not “weigh the

evidence, make credibility determinations, or attempt to determine the truth of the matter.” Id.

(internal quotation marks omitted).

DISCUSSION

Many of ETS’s claims to summary judgment turn on whether the Agreement was validly

terminated, effective July 20, 2018, by the July 13, 2018, Termination Letter. Therefore, it makes sense

to begin this analysis with ETS’s arguments for summary judgment on Counterclaim Counts I and

III—ETS’s breach of contract claim. If ETS is not entitled to judgment on those claims, neither will

it be so entitled as to Complaint Counts I, II, and VII—MWG’s claims for breach of contract and

tortious interference against ETS.

After determining whether ETS is entitled to summary judgment with respect to the above

counts, the Court will address Complaint Counts II, III, V, and VI, which relate to ETS’s alleged use

of MWG’s customer list.4. Next, the Court will address whether MWG’s claimed damages may exceed

the price it paid for Mirragen. Finally, the Court will decide upon MWG’s Motion for Leave to File a

Sur Reply.

I. Counterclaim Counts I and III—Whether MWG Materially and Incurably Breached

the Distribution Agreement

“The essential elements of a breach of contract action include: ‘(1) the existence and terms of

a contract; (2) that plaintiff performed or tendered performance pursuant to the contract; (3) breach

of the contract by the defendant; and (4) damages suffered by the plaintiff.’” Moore v. Armed Forces

Bank, N.A., 534 S.W.3d 323, 327 (Mo. App. 2017) (quoting Keveney v. Mo. Military Acad., 304 S.W.3d

98, 104 (Mo. banc 2010)). With respect to breach, Missouri follows the rule of substantial

performance. A plaintiff who receives imperfect yet substantial performance may not thereafter sue

4 MWG does not contest entry of partial summary judgment as to Complaint Counts II, III, V, and VI as they

relate to ETS’s alleged use of MWG’s DOD research, nor as to Complaint Count IV (Recoupment). Doc.

[74] at 34. Because ETS provides sufficient evidence demonstrating the absence of a genuine dispute of

material fact as to all of those claims, Doc. [64] at 20, the Court grants summary judgment on Count IV and

partial summary judgment on Counts II, III, V, and VI.

to cancel and recoup the full value of the contract. Campbell v. Shaw, 947 S.W.2d 128, 131-32 (Mo.

App. 1997). A party materially breaches when it fails to substantially perform. Fox Creek Constr., Inc.

v. Opie’s Landscaping, LLC, 587 S.W.3d 746, 750 (Mo. App. 2019) (en banc) (quoting Fire Sprinklers, Inc.

v. Icon Contracting, Inc., 279 S.W.3d 230, 233 (Mo. App. 2009)). When a defendant commits a material

breach, the aggrieved plaintiff is excused from performing, may cancel the contract, and may sue for

damages. Campbell, 947 S.W.2d at 131. Whether a breach is material is a question of fact to be

determined after considering “the degree of hardship on the breaching party and the extent to which

the aggrieved party has received the substantial benefit of the promised performance and the adequacy

with which he may be compensated for partial breach by damages.” Id. at 131-32 (quoting Murphy

Leasing Co., 895 S.W.2d at 609).

ETS argues that it is entitled to judgment as a matter of law on Counterclaim Count I because

MWG materially and incurably breached the Agreement by (i) failing to use “best efforts” to sell

Mirragen, (ii) failing to keep and provide to ETS appropriate records regarding MWG’s Mirragen sales,

and (iii) selling Mirragen to persons and entities that were not “hospitals or appropriate medical

facilities.” Doc. [64] at 7, 10, 13. And on the same grounds, ETS contends that it is entitled to

judgment as a matter of law on Counterclaim Count III, Complaint Count I, and Complaint Count

VII, and to partial summary judgment on Complaint Count II. Doc. [63] ¶¶ 4, 6, 7, 8. The Court

evaluates the three purported breaches of contract in turn.

A. Whether MWG “use[d] its best efforts” to sell Mirragen is genuinely disputed.

Paragraph 2.1 of the Agreement obligates MWG to “use its best efforts to promote,

demonstrate, stimulate interest in, solicit orders for and sell [Mirragen] in an end-user environment[.]”

Doc. [64-1] ¶ 2.1. ETS argues that MWG failed to use “best efforts” to solicit interest in and sales of

Mirragen, Docs. [63] ¶ 5.a, [64] at 7-8, because “[a]s of the date [it] sent the Termination Letter, MWG

had sold approximately 1.61% of the Mirragen it purchased from ETS.” Doc. [64] at 8. Of the 1.61%

sold, ETS states that more than 62.8% was sold outside the exclusive territories and to non-“end-

users.” Id. ETS further contends that, by the date of the Termination Letter, MWG had made only

one sale to the U.S. federal government and no sales in Louisiana, Tennessee, Arkansas, and Florida.

Id. ETS argues that by the end of the initial Agreement period, MWG had only twelve customers5

and, of those twelve, two were MWG’s sub-distributors and one was a Saudi Arabian business engaged

5 In its Memorandum in Support, ETS claims that MWG had only 10 customers as of the notice date. In reply

to MWG’s response to ETS’s Statement of Uncontroverted Material Facts, Doc. [80], ETS acknowledges that

MWG had sold to 12 entities at the time of notice. Id. ¶ 5.

in the automotive parts industry. Id. Lastly, ETS claims that MWG failed to respond to potential

leads. Docs. [64] at 9, [80] ¶ 7.

It is unclear how ETS arrived at 1.61% as an estimate of how much of its purchased Mirragen

MWG had sold by July 13, 2018. ETS says it reached that percentage by dividing the total number of

units sold by MWG (reflected in Exhibit G to ETS’s Motion, Doc. [64-7]) by the total number of

units MWG purchased, Doc. [80] ¶ 4, and that it determined the total amount of Mirragen purchased

by MWG by adding (i) the total units sold (reflected in Exhibit G to ETS’s Motion), (ii) the total

number of units given away by MWG as samples (reflected in Exhibit G to ETS’s Reply in Support,

Doc. [74-7]), and MWG’s remaining inventory (reflected in MWG’s Answer to Interrogatory #4, Doc.

[64-2] ¶ 4). Id. Using the same sources, the Court calculates Mirragen units MWG sold as a percentage

of the units it purchased as 1.65%.6 Regardless, ETS has failed to demonstrate that no genuine dispute

exists about the ratio of MWG’s sales to purchases. ETS claims that the cited percentage reflects the

total percentage of units sold as of the notice date (i.e., July 13, 2018). Doc. [80] ¶ 4. Yet, in performing

the calculation, ETS used total number of units sold, even though many of the units are listed in the

exhibit as having been sold after July 13, 2018.7 Id.

ETS’s claim that 62.8% of MWG’s Mirragen sales were made to non-“end users” and

purchasers outside MWG’s exclusive territory is also insufficiently substantiated. Doc. [64] at 8. It is

unclear how ETS arrived at 62.8%.8 Exhibit G does not define who is an “end-user” or where each

purchaser resides; it identifies “all customers” that purchased Mirragen from MWG, specifying only

the date of the order, the product code name, and the quantity. See Doc. [64-7] ¶ 5.

6 MWG sold 273 units of Mirragen. Doc. [64-7] at 2-4. MWG gave away 225 units. Doc. [79-7] at 1-2. And

MWG retained 16,030 units. Doc. [64-2] ¶ 4. The sum of the units MWG sold, gave away, and retained is

16,528, and 273 divided by 16,528, rounded to the nearest hundredth of a percent, is 1.65%.

7 Admittedly, had ETS excluded MWG’s sales occurring after July 13, 2018, when making its calculation, the

proportion of Mirragen purchased to Mirragen sold would be even smaller, which would arguably strengthen

ETS’s argument that MWG failed to use its best efforts. The difference does not change the Court’s finding

that ETS failed to carry its burden.

8 Trying to cite to MWG’s Answer to Interrogatory #5, ETS accidentally cites to Exhibit F—ETS’s

Supplemental Answer to MWG’s First Interrogatories. Doc. [64] at 8 (citing Doc. [64-6] (Exhibit F)). Even if

ETS had cited the proper exhibit, how ETS reached 62.8% remains unclear. Doc. [64-7] at 2-4 (MWG’s

Supplemental Answer to ETS’s First Interrogatories).

ETS claims that, as of July 13, 2018:

“three units were sold in Oklahoma (to one of MWG’s sub-distributors), six units were

sold to the U.S. Department of Veterans Affairs, 97 units were sold in Texas (including

three units to one of MWG’s sub-distributors), and 163 units were sold in Saudi

Arabia.”

Doc. [80] ¶ 6 (citing Doc. [64-7] at 2-3). Neither party disputes that MWG made no sales in Louisiana,

Tennessee, Arkansas, or Florida. Doc. [80] ¶ 6. ETS also complains that MWG sold Mirragen to only

12 customers as of the notice date. Doc. [80] ¶ 5.

Missouri law recognizes the validity of distribution agreements obligating a distributor to

employ “best efforts” to sell a producer’s goods to downstream consumers. Little Rock Surgical Co. v.

Bowers, 42 S.W.2d 367, 369 (Mo App. 1931); Warren v. Ray Cnty. Coal Co., 207 S.W. 883, 885 (Mo. App.

1919) (“Defendant seems possessed of the idea that, to make the contract valid, plaintiff should have

obligated himself in any event to sell the entire output of coal; but we think there may be a valid

obligation to try to do a thing as well as to succeed in doing it.”) (emphasis added); cf. Magruder Quarry & Co.,

LLC v. Briscoe, 83 S.W.3d 647, 650-51 (Mo. App. 2002). While the validity of such a provision is

uncontroversial, the question of whether a party substantially performed under such an obligation is

highly fact-intensive. See, e.g., LeMond Cycling, Inc. v. Trek Bicycle Corp., 2009 WL 10678239, at *8 (D.

Minn. Dec. 4, 2009); Levin v. Grecian, 974 F. Supp. 2d 1114, 1123-24 (N.D. Ill. 2013); cf. Alice Blake, Inc.

v. Hoffman, 620 S.W.2d 20, 22 (Mo. App. 1981). This case is no exception.

MWG cites evidence contextualizing the marketplace at the time Mirragen was developed and

brought to consumers. According to MWG, ETS was caught off guard by Mirragen’s quick FDA

approval.9 Ted Day, ETS’s President, told Senator Roy Blunt and the Rolla Daily News during an

April 2017 ETS facility visit that “our five month deal [to obtain Mirragen approval] . . . caught us by

surprise. We thought it would be 12 months.” Doc. [74-3] at 5. As a “start-up,” ETS had never sold

a medical device before Mirragen, Doc. [64-18] at 31:11-19, and by January 2017, about four months

after receiving FDA approval, Mirragen had not yet hit the market. Doc. [64-9] at 22:18-23:9.

When ETS and MWG negotiated the distribution agreement in July 2017, nearly 10 months

after receiving FDA approval, Mirragen still had not reached the market. Id. at 254:4-13. MWG offers

9 Specifically, ETS applied to the FDA on April 15, 2016, for a “510(k) Premarket Notification” so ETS could

market Mirragen as a medical device, Doc. [74] at 7 (citing [74-1] at 2), and ETS received approval on September

15, 2016, just five months after submitting its application. Id. (citing Docs. [74-1] at 1, [74-2] at 2).

evidence indicating that both ETS and MWG understood that a reimbursement code, a code which

allows a medical device purchaser to bill the institutional payors such as an insurer or the federal

government, Doc. [74] at 8 (citing Doc. [64-11] at 41:21-42:5), is a “vital part of the medical coding

and insurance reimbursement process,” and “essential for selling the product to private hospitals and

medical practices[.]” Docs. [1] ¶ 22, [15] ¶ 22. Without a reimbursement code, “insurers generally

will not pay for the product.” Docs. [1] ¶ 22, [15] ¶ 22. Chad Lewis, ETS’s former consultant and

eventual CEO, testified that “within [the United States], our government as well as insurance agencies

that reimburse and pay for healthcare costs—particularly in the outpatient settings—require a product

code, HCPCS code or something like that[.]” Doc. [64-9] at 50:12-18. Lewis stated that by the time

he left his role as CEO in November 2018, he was of the opinion that it would be necessary to obtain

an “A code” to successfully market Mirragen in the outpatient setting. Id. at 53:14-22. Lewis further

testified that, by that time, “the picture became clearer on what the limitations on marketing [Mirragen]

for the price that our distributor said that they can sell for. There was a conflict there. The business

model didn’t make sense.” Id. at 55:12-16.

According to Lewis, MWG told ETS before entering the Agreement that a reimbursement

code would “increase [MWG’s] channels” for Mirragen sales. Id. at 73:13-74:14. Asked whether he

had discussed the importance of a reimbursement code with Day or Lewis, Marc Gunderson, the sole

proprietor of MWG, Doc. [64-4] at 10:16-20, testified that he had discussed the reimbursement code

in “[e]very single conversation I had with Chad—and Chad knew it. Chad knew it to where he started

calling Will [Gunderson] and stopped calling me as much. I had to insist upon him calling me and he

knew the first conversation was always going to be the reimbursement code.” Doc. [64-4] at 320:23-

321:6. Asked whether he would have entered the Agreement had he been told at the onset that no

reimbursement code was forthcoming, Marc testified: “[a]bsolutely not.” Id. at 321:7-14. Lewis

acknowledged that before ETS and MWG executed the Agreement, ETS represented to MWG that

it would make efforts to obtain a reimbursement code for Mirragen, Doc. [64-9] at 74:25-75:8, and

while ETS was never contractually obliged under the Agreement to obtain a code, the Agreement

reflects this understanding. Compare Doc. [64-1] ¶ 8.2, with id. ¶ 8.3 (providing different term-

lengthening provisions for the pre-reimbursement and post-reimbursement code periods). Marc

Gunderson further confirmed that MWG expected a forthcoming code, testifying that MWG’s

obligation to satisfy the “minimum Annual Sales Metric” referenced in ¶ 1.3, see Doc. [64-1] ¶ 1.3, was

introduced to assure that MWG purchased Mirragen from ETS to “build up stock until we got a

code.” Doc. [64-4] at 194:18-195:8; see also Doc. [64-1] at 20 (defining “MIRRAGEN Minimum Sales”

as “product purchased from ETS Wound Care”). In sum, MWG presents ample evidence that a

reimbursement code was important for the marketing of Mirragen, such that the failure to acquire a

code would inhibit MWG’s ability to sell the product.

In addition, MWG presents evidence indicating that it took considerable efforts to bring

Mirragen to market. MWG cites Marc Gunderson’s testimony that MWG formed a team of about 15

employees and 10 independent representatives, Doc. [64-4] at 109:23-110:2, and opened a call center

to generate both sales and leads, id. at 110:13-111:9. According to Exhibit N,10 MWG made 730

contacts with around 278 or so entities by July 13, 2018.11 Doc. [71] (Ex. N).

Whether an entity employed “best efforts” is a highly fact-specific question that has to be

decided in a particularized context. LeMond Cycling, Inc., 2009 WL 10678239, at *8 (“[D]etermining

whether a party has exerted its ‘best efforts’ is dependent upon the factual circumstances surrounding

the contractual agreement.”) (quoting Martin v. Monumental Life Ins. Co., 240 F.3d 223, 233 (3d Cir.

2001)). Given evidence that the lack of a reimbursement code impeded MWG’s efforts to sell

Mirragen and that MWG took appreciable efforts to bring the product to market despite that

impediment, a genuine dispute remains over whether MWG’s efforts were enough to satisfy its

obligation to employ “best efforts.” LeMond Cycling, Inc., 2009 WL 10678239, at *8 (“[C]ompliance

with a best-efforts clause is a question of fact for the jury.”) (quoting Minneapolis Cmty. Dev. Agency v.

Lake Calhoun Assocs., 928 F.2d 299, 301 (8th Cir. 1991) (applying Minnesota law)).

Finally, ETS maintains that MWG did not use its “best efforts” because it failed to respond

to various provided leads. Doc. [64] at 9. ETS states that on October 31, 2017, Chad Lewis sent an

email to Marc, Sam, and Will Gunderson in which Lewis provided the names and addresses of nine

individuals from eight hospitals or medical facilities. Doc. [64] at 9 (citing Doc. [64-13]). According

to Lewis, the nine individuals demonstrated interest in Mirragen at the Fall Symposium on Advanced

Wound Care (SAWC) conference. Id. (citing Doc. [64-13]). ETS claims that MWG failed to contact

10 ETS filed Exhibits N, P-1, Q-1 and R-1 on a flash drive deposited with the Clerk’s Office. Docs. [65], [71].

11 MWG claims that Exhibit N indicates that MWG contacted 1,022 individual entities, Doc. [74] at 19, but

Exhibit N lists many repeated contacts with the same entities. See Doc. [71] (Ex. N). In reply, ETS clarifies

that the Exhibit identifies around 278 different entities purportedly contacted by MWG by July 13, 2018. Doc.

[79] at 4. Even as re-construed, Exhibit N supports the inference that MWG made efforts to bring Mirragen

to market, creating a genuine dispute of material fact about whether its efforts satisfied its “best efforts”

obligation.

eight of the nine individuals. Id. (citing Doc. [71] (Ex. N)). ETS also notes that on May 1, 2018, an

ETS employee sent an email to Sam Gunderson providing the contact information of 15 individuals

associated with various medical facilities that were interested in Mirragen at the Spring SAWC

conference. Id. (citing Doc. [64-14]). In response, Gunderson emailed back, “[w]e will contact the

leads within our states immediately.” Id. (citing Doc. [64-14]). ETS maintains that MWG contacted

only two of the 15 individuals. Id. (citing Doc. [71] (Ex. N)).

MWG counters that ETS cherry-picks fewer than two-dozen sales leads with which MWG

failed to follow up, while there is evidence indicating that MWG contacted no fewer than 1,022 entities

in effort to sell Mirragen. Doc. [74] at 19. MWG references Exhibit N which purports to document

over a thousand contacts MWG made with actual and potential Mirragen customers, listing the name

of the actual or potential customer, the customer representative’s name, the product line (i.e.,

Mirragen), the current step in the sales process, and additional information explaining the contact.

Doc. [71] (Ex. N). In reply, ETS contends that while Exhibit N contains 1,023 rows, it identifies only

278 distinct entities purportedly contacted by MWG before July 13, 2018. Doc. [79] at 4.

Evidence of MWG’s efforts to contact 278 prospective Mirragen customers does create a

genuine dispute as to whether MWG’s failure to contact certain other prospective customers qualifies

as a failure to use its “best efforts” to sell Mirragen.

B. Whether MWG violated its recordkeeping and disclosure obligations under ¶¶ 3.5,

3.8, and 8.7 is genuinely disputed.

ETS claims that MWG’s recordkeeping was deficient in two ways: (1) MWG failed to keep

the records that it was supposed to keep and provide the records it was supposed to provide, and

(2) MWG misrepresented its real sales numbers. Doc. [64] at 10-13.

In relevant part, paragraph 8.7 of the Agreement requires MWG to “keep full and proper

books of account and records only relating to [Mirragen] purchases, sales, returns, warranty claims,

customer complaints, regulatory matters and [MWG’s] compliance with the terms of this Agreement

and applicable laws, including but not limited to the Foreign Corrupt Practices Act.” Doc. [64-1]

¶ 8.7. Paragraph 3.5 obligates MWG to retain “records . . . regarding the distribution or use of

[Mirragen] by lot number” and to “make those numbers and the respective tracking information

available” to ETS. Id. ¶ 3.5. Paragraph 3.8 prohibits MWG from “directly or indirectly mak[ing] any

representation, statement or disclosure of a material fact relating to or affecting [ETS’s] interests” that

is “deceptive, misleading or false in its form or content.” Id. ¶ 3.8. Paragraph 8.5.2 authorizes ETS,

upon giving notice to MWG, to “terminate this Agreement prior to the expiration of the Initial Term

or any Renewal Term upon the occurrence and in the time frame specified of any of the following: . .

. effective immediately. . . upon the making of any material misrepresentation by [MWG] to [ETS] or

any customer or any potential customer of [Mirragen] or the discovery of the same by [ETS].” Id. ¶

8.5.2.

According to Chad Lewis, ETS requested sales records from MWG “more than a dozen

times,” and MWG responded by submitting incorrect records and refusing to provide the proper ones.

Doc. [64] at 10 (citing Doc. [64-9] at 278:10-279:11). Lewis testified that ¶¶ 8.7 and 3.5 were intended

to allow ETS to trace product for regulatory purposes as well as to verify Mirragen sales. Id. (citing

Doc. [64-9] at 272:20-273:17, 277:13-18).

MWG counters that the cited paragraphs do not obligate MWG to transmit sales records to

ETS: ¶ 8.7 does require MWG to retain sales records, among other things, but ¶ 3.5 does not require

that the information covered in ¶ 8.7 be shared. Doc. [74] at 19-20; compare Doc. [64-1] ¶ 8.7, with id.

¶ 3.5. The Court agrees. The plain language of ¶ 3.5 requires only that MWG maintain records

regarding use or distribution of Mirragen “by lot number” and make such numbers and relevant

“tracking information” available to ETS. Doc. [64-1] ¶ 3.5. It does not incorporate the records

covered by ¶ 8.7. Id. In fact, ¶ 8.7 includes a separate mechanism by which ETS might review records

covered by ¶ 8.7, including MWG’s Mirragen sales records: ETS may audit MWG’s business records

“related to [Mirragen] upon reasonable notice[.]” Id. ¶ 8.7.

MWG concedes that ETS asked for records, and ETS acknowledges that MWG provided

records, just the wrong ones. Doc. [74] at 25 (quoting Doc. [64] at 10). MWG offers the testimony

of Sam Gunderson that while “lot numbers were tracked as product went out the door[,]” Doc. [74]

at 25 (quoting Doc. [64-11] at 117:11-12), ETS “never requested” product information by lot number

even though MWG “kept that and had it available at any point in time.” Id. (quoting Doc. [64-11] at

117:17-18). Given the proper understanding of the Agreement and the conflicting testimony cited by

the parties, there is a genuine dispute of material fact as to whether MWG failed to keep and provide

proper records under ¶¶ 3.5 and 8.7.

ETS argues that there is no genuine dispute of material fact that MWG thrice violated ¶ 3.8

by misrepresenting its sales data. Doc. [64] at 10-12. MWG protests that the allegation “that the sales

records MWG provided to ETS were false and therefore violated ¶ 3.8 of the Agreement” is a “brand-

new allegation, never made in any pleading or correspondence before ETS filed its Motion[,]” Doc.

[74] at 26, and thus it should not be considered by the Court. Id.

On review of ETS’s Counterclaim, Doc. [15], and Amended Counterclaim, Doc. [31], the

Court finds that MWG is correct. ETS did not plead that MWG breached ¶ 3.8 by transmitting

incorrect sales data. ETS alleged that MWG violated ¶ 3.8 only by allowing Dr. David Ellis, MWG’s

medical director, to present himself to potential customers as a medical director for ETS.12 Docs. [15]

at 40, ¶¶ 64-67, [31] ¶¶ 64-67. Thus, ETS seeks summary judgment for breach of ¶ 3.8 on factual

grounds not pled in the operative pleading.

It is improper for a plaintiff to raise new claims at summary judgment that have not been

alleged within its complaint. While pleading under Federal Rule of Civil Procedure 8(a) requires

district courts to construe complaints liberally, such “liberal” construction is “‘inapplicable after

discovery has commenced” because “[a]t the summary judgment stage, the proper procedure for [a]

plaintiff[ ] to assert a new claim is to amend the complaint in accordance with Fed. R. Civ. P. 15(a).’”

WireCo WorldGroup, Inc. v. Liberty Mut. Fire Ins. Co., 231 F. Supp. 3d 313, 317-18 (W.D. Mo. 2017), aff’d,

897 F.3d 987 (8th Cir. 2018) (quoting Gilmour v. Gates, McDonald & Co., 382 F.3d 1312, 1315 (11th

Cir. 2004)); see also N. States Power Co. v. Fed. Transit Admin., 358 F.3d 1050, 1057 (8th Cir. 2004). That

makes sense, as the allegations in pleadings frame the scope of the dispute between the litigants.

Where discovery unveils new facts that support an alternative basis for relief, the claimant should seek

to amend its operative pleading to include the additional factual allegations. See Fed. R. Civ. P. 15(a).

By amending, the claimant gives the opposing party notice and opportunity to develop its arguments

to confront a new claim. Raising a new theory at summary judgment without prior amendment of the

pleading deprives the opposing party of the fair notice that the federal pleading rules are designed to

provide. See WireCo WorldGroup, Inc. v. Liberty Mut. Fire Ins. Co., 897 F.3d 987, 992-93 (8th Cir. 2018)

(quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007)).

Here, ETS’s Amended Counterclaim was specific as to “the nature, bases, and grounds of

[MWG’s] alleged breaches of contract.” Id. at 993; see also Doc. [31] ¶¶ 16-140. It contained no

allegations that would have put MWG on notice that ETS sought to hold it liable for breach of ¶ 3.8

on account of material misrepresentations contained in MWG’s submitted sales data. Allowing such

allegations to be raised for the first time on summary judgment would be especially problematic since,

12 ETS does not argue for summary judgment on Count II for breach of ¶ 3.8 on those grounds.

if pled, they might have been subject to Federal Rule of Civil Procedure 9(b)’s heightened pleading

requirements.13 See Fed. R. Civ. P. 9(b); cf. Allstate Indem. Co. v. Dixon, 304 F.R.D. 580, 583-84 (W.D.

Mo. Feb. 12, 2015) (recognizing that Rule 9(b) applies to contract-based fraud claims as well as

common law fraud claims) (quoting Hendley v. Am. Nat. Fire. Ins. Co., 842 F.2d 267, 268 (11th Cir.

1988)). ETS’s counterarguments do not outweigh the fact that the Amended Counterclaim gave no

notice that ETS intended to press a charge of material misrepresentation,14 and so the Court declines

to consider the unpled grounds for relief.

C. Whether MWG sold to entities that were not “hospitals or appropriate medical

facilities” is genuinely disputed.

The Agreement authorizes MWG to “sell [Mirragen] in an end-user environment to ensure

the highest quality of pre-sale and post-sale support to customers,” Doc. [64-1] ¶ 2.1, provided MWG

does not sell to “any person or entity other than a hospital or appropriate medical facility.” Id. ¶ 2.3.

ETS claims that MWG breached those restrictions when it sold Mirragen to Life with Doctors,

Elevated Marketing, and Wellness Ocean Trading. Docs. [64] at 8, 13, [80] ¶ 11.

According to ETS, as “sub-distributors,” Life with Doctors and Elevated Marketing are not

“hospitals or appropriate medical facilities.” Docs. [64] at 8, 13, [80] ¶ 11 (citing the distribution

agreements between MWG and the two entities, Docs. [64-12], [64-19]). MWG responds that the

Agreement does not define “appropriate medical facility.” Doc. [80] ¶ 11.

Determining whether Life with Doctors and Elevated Marketing are “hospitals or appropriate

medical facilities” requires construction of the Agreement. “‘The cardinal rule in contract

interpretation is to ascertain the intention of the parties and to give effect to that intention.’” ATC

Co., Inc. v. Myatt, 389 S.W.3d 732, 735 (Mo. App. 2013) (quoting Renco Grp., Inc. v. Certain Underwriters

13 In its Memorandum in Support, ETS asserts that sales information MWG provided was “false and

fraudulent.” Doc. [64] at 14.

14 ETS argues that its properly pled allegations relating to MWGs failure to keep and provide records as well as

the July 13, 2018, Termination Letter put MWG on notice of its misrepresentation claim under ¶ 3.8. Doc.

[79] at 11-12. That is incorrect. First, while the July 13th Letter may hint at a misrepresentation claim, it is not

a pleading that circumscribes the scope of this litigation. Second, the Amended Counterclaim’s allegations

concerning MWG’s proffered sales data relate only to Agreement ¶¶ 8.7 and 3.5, not ¶ 3.8. Doc. [31] ¶¶ 17-

39. Third, the Amended Counterclaim nowhere alleges that the sales information MWG supplied were false.

Additionally, ETS has not shown that deposition testimony and other discovered materials taken together gave

sufficient notice of its intention to proceed on its unpled misrepresentation claim. See WireCo WorldGroup, 897

F.3d at 993 n.5 (interrogatories did not provide sufficient notice that party “intended to pursue a new ground”).

at Lloyd’s, 362 S.W.3d 472, 477 (Mo. App. 2012)). Whether a contract is ambiguous is a legal question

that is determined by looking at the contract as a whole and standing alone. Id. (quoting Klonoski v.

Cardiovascular Consultants of Cape Girardeau, Inc., 171 S.W.3d 70, 73 (Mo. App. 2005)); see also Teets v. Am.

Fam. Mut. Ins. Co., 272 S.W.3d 455, 462 (Mo. App. 2008), overruled on other grounds in Badahman v. Catering

St. Louis, 395 S.W.3d 29 (Mo. banc 2013). If the contract is clear and unambiguous, its meaning must

be derived from the contract’s plain language. Id. (citing Renco Grp., Inc., 362 S.W.3d at 477). But a

contract is ambiguous where, “in the context of the entire agreement, the disputed language ‘is

reasonably susceptible of more than one construction giving the words their plain and ordinary

meaning as understood by a reasonable, average person.’” Id. (quoting Klonoski, 171 S.W.3d at 73); see

also Rathbun v. CATO Corp., 93 S.W.3d 771, 778 (Mo. App. 2002) (noting that ambiguity exists where

there is “duplicity, indistinctness, or uncertainty in the meaning of the words used”) (citing Bydalek v.

Brines, 29 S.W.3d 848, 854 (Mo. App. 2000)). Once ambiguity is found, the parties’ intention becomes

a question of fact to be resolved by the trier of fact, and extrinsic evidence may be introduced. Myatt,

389 S.W.3d at 735 (citing Teets, 272 S.W.3d at 462).

The Agreement prescribes that MWG will use its best efforts to solicit and make Mirragen

sales in an “end-user environment to ensure highest quality of pre-sale and post-sale support to

customers,” Doc. [64-1] ¶ 2.1, and it prohibits MWG from selling Mirragen to “any person or entity

other than a hospital or appropriate medical facility.” Id. ¶ 2.3. The Agreement does not define

“hospital.” More importantly, it does not define “medical facility,” nor what constitutes an

“appropriate” one. The Agreement also does not define “end-user environment.”15

The term “medical facility” is susceptible to more than one interpretation. As a composite

term, it has been defined as “a place where sick or injured people are given care or treatment (as a

hospital, urgent care, or a clinic).” Medical facility, MERRIAM-WEBSTER.COM, https://www.merriam-

webster.com/dictionary/medical%20facility (last visited Feb. 14, 2022). That is the interpretation

advanced by ETS, which cites Chad Lewis’s testimony that the terms “hospital” and “appropriate

medical facility” mean “a facility that provides medical care.” Docs. [64] at 13, [64-9] at 266:11-267:3.

Lewis also testified that ¶ 2.3 was included in the Agreement to exclude sub-distributors and thereby

protect ETS’s control over Mirragen, as well as its messaging, training, and patient care. Doc. [64-9]

at 267:4-18.

15 The Agreement makes only one other reference to an “end-user” in ¶ 7.11, which notes MWG’s obligation

to notify “end-user customers” of their obligations to report discounts to government payors.

That is not the only reasonable way to interpret “medical facility,” however. The term

“medical” means “of, relating to, or concerned with physicians or the practice of medicine,” Medical,

MERRIAM-WEBSTER.COM, https://www.merriam-webster.com/dictionary/medical (last visited Feb.

14, 2022), and “facility” means “something (such as a hospital) that is built, installed, or established to

serve a particular purpose.” Facility, MERRIAM-WEBSTER.COM, https://www.merriam-

webster.com/dictionary/facilities (last visited Feb. 14, 2022). Taking those definitions together,

“medical facility” could include any institution or business established to serve a purpose related to or

concerned with the practice of medicine. Using that broader definition of “medical facility,” the

Agreement authorized the sale of Mirragen to any institution that is engaged in activities related to the

practice of medicine, so long as, per ¶ 2.1, it was sold “in an end-user environment.”

MWG’s understanding of “appropriate medical facility” aligns with the broader construction.

Marc Gunderson testified that at the time of negotiation, he understood it to include any purchasers

who would place product in “any probable position of sale to end up in the end user’s hand.” Doc.

[80] ¶ 11 (quoting Doc. [64-4] at 135:8-22). According to Gunderson, Life with Doctors was engaged

in “home care,” while Elevated Marketing sold Mirragen “hospital to hospital.” Id. (citing Doc. [64-

4] at 253:12-15, 254:25-255:7). He claims to have understood both as “appropriate medical facilities”

under the Agreement. Doc. [64-4] at 135:1-22.

The Agreement clearly contemplates that MWG will sell to entities that are not literal “end-

users” of Mirragen—i.e., patients with unhealed wounds. See Doc. [64-1] at 2.1; see also End user,

MERRIAM-WEBSTER.COM, https://www.merriam-webster.com/dictionary/end%20user (last visited

Feb. 14, 2022) (defining “end user” as “the ultimate consumer of a finished product”). The disputed

question, then, is how many steps removed an MWG customer may be from ultimate Mirragen users

before the sale violates ¶ 2.3. The Agreement itself does not resolve that question. Because the term

“appropriate medical facility” is undefined and reasonably susceptible to differing constructions, it is

ambiguous, and its scope is a question of fact to be resolved at trial. See Myatt, 389 S.W.3d at 735.

ETS claims that MWG incurably breached ¶ 2.3 by negotiating and selling Mirragen to

“Wellness Ocean Trading, a Saudi Arabian company primarily involved in the business of automobile

parts.” Docs. [64] at 13, [80] ¶ 11. According to ETS, Wellness Ocean Trading was neither a hospital

nor an appropriate medical facility and existed outside MWG’s exclusive territory. Doc. [64] at 14.

MWG responds that MWG’s business activities in the Middle East were expressly authorized by Chad

Lewis, ETS’s CEO. Doc. [74] at 20. In support of its position, MWG refers to a December 19, 2017,

email from Lewis to Marc Gunderson noting a “resulting action item” that ETS draft an amendment

to the Agreement “after reviewing Saudi Arabia regulatory requirements” and that further invited

MWG to “share information relating to Saudi Arabia regulatory registration and the process.” Doc.

[74] at 20 (citing Doc. [74-8] at 2). On January 9, 2018, MWG responded to ETS’s request by sending

an email containing information about both the Alassaf family business venture and the Food and

Drug Authority of the Kingdom of Saudi Arabia. Doc. [74-9] at 2, 4-5. Marc Gunderson testified

that Lewis told him to “[m]ake the sales and I’ll send you the agreement.” Doc. [64-4] at 251:13-20,

253:1-7. Gunderson also testified that he and five others at MWG took a two-week trip to Saudi

Arabia in April 2018 to solicit Mirragen sales, receiving “large purchase orders” from “[e]very

[government-owned] hospital in Saudi Arabia,” as well as “three private” hospitals. Doc. [64-4] at

228:1-229:17. According to MWG, ETS noted in its April 2018 board of directors’ slide deck that

ETS anticipated considerable sales in Saudi Arabia estimated at a total of $600,000 through “Atlas”

(i.e., MWG). Doc. [74] at 21 (citing Doc. [74-11] at 14). In reply, ETS notes that ¶ 15.2 of the

Agreement provides in part that “[n]o changes or modifications of or additions to this Agreement

shall be valid unless the same shall be in writing and signed by each Party thereto.” Doc. [79] at 13

(quoting Doc. [64-1] ¶ 15.2). While the proposed amendment authorizing MWG’s business activity

in Saudi Arabia was drafted in January 2018, ETS argues, it was never executed, and so MWG cannot

rely upon Lewis’ authorization. Doc. [79] at 13 (citing Doc. [64-4] at 251:24-252:23).

It is well-settled under Missouri law that “‘[a]n express provision in a written contract that no

rescission or variation shall be valid unless it too is in writing is ineffective to invalidate a subsequent

oral agreement to the contrary.’” Jennings v. SSM Health Care St. Louis, 355 S.W.3d 526, 535 (Mo. App.

2011) (quoting Fritts v. Cloud Oak Flooring, 478 S.W.2d 8, 14 (Mo. App. 1972) (quoting 3A CORBIN ON

CONTRACTS § 763)); see also Doss v. EPIC Healthcare Mgmt. Co., 901 S.W.2d 216, 211 (Mo. App. 1995);

Rufkahr Constr. Co. v. Weber, 658 S.W.2d 489, 498 (Mo. App. 1983) (en banc). The evidence cited by

MWG provides an adequate basis to support a finding that MWG and ETS modified the Agreement

to allow the former to solicit and enter Mirragen sales in Saudi Arabia with Ocean Wellness Trading

Co. despite the limitations to modification imposed by ¶ 15.2.

Because there are genuine disputes of material fact as to whether MWG used “best efforts” as

required by ¶ 2.1; kept and provided appropriate records to ETS as prescribed by ¶¶ 3.5 and 8.7; and

sold only to entities that were “hospitals and appropriate medical facilities” as dictated by ¶¶ 2.1 and

2.3, ETS is not entitled to summary judgment as to Counterclaim Counts I and III.

II. Complaint Counts I, II, and VII—MWG’s Claims for Breach of Contract and Tortious

Interference Concerning ETS’s Actions to Terminate the Agreement and Employ

Alternative Distributors

ETS claims that, because the Agreement was validly terminated on July 20, 2018, it is entitled

to judgment as a matter of law on Complaint Counts I, II,16 and VII. Doc. [64] at 14-15. Having

found that there are genuine disputes of material fact preventing summary judgment as to whether

ETS validly terminated the Agreement on account of MWG’s pre-July 13, 2018, breaches of contract,

the Court further finds that ETS is not entitled to summary judgment on Complaint Counts I, II, and

VII.

III. Complaint Counts II, III, V and VI—MWG’s Breach of Contract and Trade Secret

Claims Based on ETS’s Use or Disclosure of MWG’s Customer List

ETS also moves for summary judgment as to all of MWG’s claims that relate to ETS’s alleged

disclosure and misuse of MWG’s “customer list.” MWG claims that ETS’s use of its customer list

violated the terms of both the Agreement and the NDA and both federal and state trade secret laws.

Doc. [1] ¶¶ 83, 100, 105-112, 131, 135-140, 148. All of MWG’s claims relating to the customer list

rest on two factual allegations: (1) that ETS used MWG’s customer list, and (2) that ETS provided

that list to third-parties. Doc. [1] ¶¶ 83, 96, 105, 108, 135-140, 146-149.

The NDA, which the Agreement incorporated, see Doc. [64-1] ¶ 6, provides that signatories

thereto “will hold in strict confidence and not disclose to any third party any Confidential

Information.” Doc. [1-2] ¶ 2. The NDA also prohibits any party receiving Confidential Information

from using the same for a purpose other than a Permitted Use. Id. ¶ 2. The NDA broadly defines

“Confidential Information” as “any and all technical and nontechnical information disclosed by [a

party] to [the other party][,]” id. ¶ 1, and includes, without limitation, “trade secrets,” and “proprietary

confidential information . . . related to the current, future, and proposed products and services of

[each party], such as information concerning research, experimental work, development, [and] . . .

customer lists[.]” Id. The Agreement provides that, in the event of conflict, the Agreement supersedes

16 ETS asserts that because the Agreement was terminated, it is entitled to summary judgment with respect to

MWG’s claims that ETS improperly terminated the Agreement and employed alternative distributors in the

exclusive territory. Doc. [64] at 15-16. ETS’s request for summary judgment on Count II’s grounds relating

to ETS’s purported disclosure or use of MWG’s customer list will be addressed separately.

the NDA, Doc. [64-1] ¶ 6.1, and ¶ 8.10 guarantees that the obligations of the NDA continue after the

Agreement is terminated.17

MWG claims that, in addition to breaching both the Agreement and the NDA, ETS’s

treatment of its customer list violated the federal Defend Trade Secrets Act (DTSA) and the Missouri

Uniform Trade Secrets Act (MUTSA). Doc. [1] ¶¶ 131, 135-140, 146, 148-149. In order to prevail

on a claim under either statute, MWG must show: (i) that it held a protectable trade secret, (ii) that

ETS misappropriated that secret, and (iii) damages. CGB Diversified Servs., Inc. v. Baumgart, 504 F. Supp.

3d 1006, 1020 (E.D. Mo. 2020). To qualify as a trade secret, the subject-matter must meet two

conditions: first, that “its owner has taken reasonable measures to keep it secret,” and second, that

“it derives independent economic value from not being known or easily ascertainable by another

person who can obtain economic value from it.” Perficient, Inc. v. Munley, 2019 WL 4247056, at *9

(E.D. Mo. Sept. 5, 2019) (citing 18 U.S.C. § 1839(3); MO. REV. STAT. § 417.453(4)). “Misappropriation

of trade secrets ‘occurs when (1) a person acquires the trade secret while knowing or having reason to

know that he or she is doing so by improper means, (2) a person who has acquired or derived

knowledge of the trade secret discloses it without the owner’s consent, or (3) when a person who has

acquired or derived knowledge of the trade secret uses it without the owner’s consent.’” Baumgart,

504 F. Supp. 3d at 1020 (citing Cori, 2016 WL 6611133, at *2).

In their summary judgment briefing, neither party questions whether the customer list qualifies

as “Confidential Information” under the NDA or a protectable trade secret under the DTSA or

MUTSA. Docs. [64] at 17-19, [74] at 32-34. Rather, ETS argues that it is entitled to summary judgment

as to all of the claims based on the customer list for two reasons: (1) there is no evidence that ETS

improperly used or disclosed the customer list, and (2) (as an alternative basis for summary judgment

on the trade secret claims) even if ETS had done either, there is no evidence that it derived any

economic benefit therefrom. Doc. [64] at 17-19.

Regarding disclosure of the customer list, ETS points to testimony from MWG officials

disclaiming knowledge that ETS had shared the customer list, Doc. [64] at 17-18 (citing Docs. [64-4]

at 238:14-21, [64-11] at 104:22-106:14). ETS’s Chad Lewis also emphatically denied it. Id. at 18 (citing

Doc. [64-9] at 83:10-13). And in fact, MWG concedes that ETS did not share the entire customer list

with any third party. Doc. [80] ¶ 16.

17 The parties agree that the NDA remained in force at all relevant times. Docs. [1] ¶ 12, [15] ¶ 12. The NDA

states that it will terminate five (5) years after June 12, 2017, Doc. [1-2] ¶ 9, and that both MWG and ETS’s

obligations survive the NDA’s termination. Id.

With respect to MWG’s allegations that ETS misused the customer list, ETS contends that

there is no evidence that it improperly contacted MWG’s customers, citing testimony from Lewis Hall,

the owner of GMM, indicating that Hall was aware of MWG’s customers based on his own

involvement when the Agreement was signed. Doc. [64] at 18 (citing Doc. [64-20] at 46:7-15). Some

of the entities MWG identified as customers were not customers at all, ETS argues, for example

Deborah Floyd and Eugene Grayfer were MWG’s “sub-distributors.” Doc. [64] at 18-19 (citing Doc.

[64-7] ¶ 5).18 And another putative customer was identified to ETS independently in relation to a

possible clinical study, Doc. [64] at 19 (citing Doc. [64-9] at 85:16-86:6), and never purchased Mirragen

from MWG. Doc. [64-7] ¶ 5.

MWG replies with additional evidence that, it believes, indicates that ETS misused MWG’s

client list. Specifically, on December 6, 2018—six months after MWG disclosed its customer list

identifying Hines Veterans Affairs Hospital as one of its customers—an employee of ETS emailed

the operator of a prospective distributor noting that, as that prospective distributor was aware, ETS

was trying to replace the product VA Hines had purchased from MWG, and encouraged him to “build

a relationship” with VA Hines. Doc. [74] at 33 (citing Docs. [74-19] at 1, 15, [74-25] at 2-3). ETS

claims that it had information about VA Hines before receiving MWG’s customer list,19 and that VA

Hines reached out to ETS before ETS engaged the new distributor to supply the hospital. Doc. [79]

at 14-15 (citing Doc. [64-9] at 255:23-256:20).

While ETS’s evidence provides a plausible alternative explanation of the communication

between ETS and VA Hines after ETS received MWG’s customer list, it does not foreclose the

possibility that ETS misused MWG’s customer list. A material fact need not “be resolved conclusively

in favor of the party asserting its existence; rather, all that is required is that sufficient evidence

supporting the claimed factual dispute can be shown to require a jury or judge to resolve the parties’

differing version of the truth at trial.” First Nat. Bank of Ariz. v. Cities Serv. Co., 391 U.S. 253, 288-89

(1968). Here, each party provides substantial evidence to support its side of the story. Resolving the

18 ETS claims that “Chad Lewis recalled contacting Grayfer ‘to notify [him] that MWG was no longer the

distributor’” without knowing whether Grayfer was a customer. Doc. [64] at 19 (citing Doc. [64-9] at 85:1-10).

That Lewis was referring to Grayfer is not apparent from the cited testimony. Asked whether he remembered

the “one customer” he notified, Lewis testified that he thought it was a home health organization and did not

remember its name. Doc. [64-9] at 85:7-13.

19 ETS claims that it sent MWG an email on November 2, 2017, containing Nancy Chaiken’s contact

information and listing Hines VA as a potential customer. Doc. [79] at 14 (citing Doc. [79-3]).

issue will require making credibility determinations about the provided evidence, which is outside the

scope of summary judgment. Anderson, 477 U.S. at 249.

Because the alleged misuse or disclosure of the customer list is genuinely disputed, so is the

question of whether ETS realized any economic benefit therefrom: If ETS used MWG’s customer

list to identify VA Hines as a potential customer, then there is evidence in the record that it realized

an economic benefit from use of the list; if its relationship with VA Hines has an innocent origin, then

so do those economic gains. Thus, ETS’s alternative argument for summary judgment on Complaint

Counts VI and VII also fails.20

IV. Deciding Summary Judgment on MWG’s Claimed Damages is Premature

ETS notes that “[i]n its Complaint, MWG seeks actual damages, punitive damages,

recoupment of out-of-pocket losses no less than $2 million, and attorney’s fees,” and claims that

because “the Agreement limits damages incurred by ETS to the amount actually paid by MWG to

ETS for its purchase of Mirragen,” ETS is entitled to summary judgment on “any damages that

exceed” that amount. Doc. [64] at 21-22. Because the issue may be entirely avoided if, at trial, MWG

fails to prove its case, it is unripe for a ruling at this time. Neb. Pub. Power Dist. v. MidAmerican Energy

Co., 234 F.3d 1032, 1039 (8th Cir. 2000) (“Judicial resolution of a legal question fit for judicial review

yet portending no immediate hardship would constitute little more than a law review article.”).

V. MWG’s Motion for Leave to File a Sur Reply Is Denied As Moot

On May 14, 2021, MWG filed a Motion for Leave to File a Sur-Reply, Doc. [82], in response

to arguments raised by ETS in its Reply, Doc. [79]. MWG contends that ETS neither argued in its

20 ETS’s argument based on lack of economic benefit fails on the basis of the factual record, and MWG does

not question its legal merits, so the Court has not had the benefit of adversarial briefing on that issue.

Nevertheless, it notes that the legal authority cited by ETS does not obviously support the claim that MWG

must prove that ETS acquired an economic benefit to prevail on its civil trade secret causes of action. In

Perficient, the court cites 18 U.S.C. § 1832(a) and MO. REV. STAT. § 417.455 for the proposition that the DTSA

and MUTSA make it illegal to misappropriate trade secrets “for the purpose [of receiving an] economic benefit.”

Perficient, 2019 WL 4247056, at *9. MO. REV. STAT. § 417.455 authorizes injunctive relief against actual or

threatened misappropriation to eliminate any commercial advantage derived from the misappropriation. 18

U.S.C. § 1832(a) defines the federal crime of trade secret theft, and the “economic benefit” language is contained

in the portion of the statute defining the requisite mens rea for the offense. 18 U.S.C. § 1832(a) (“Whoever, with

intent to convert a trade secret . . . to the economic benefit of anyone other than the owner thereof, and

intending or knowing that the offense will, injure any owner of that trade secret, knowingly—. . . .”). The

federal private right of action for misappropriation of trade secrets—i.e., the right of action at issue in this

lawsuit—is provided in 18 U.S.C. § 1836(b). See Eberline Oilfield Serv., Inc. v. Eberline, 2020 WL 6233330, at *6

(D.N.D. March 6, 2020) (“While § 1832, a criminal statute, does not itself provide a private civil cause of action,

§ 1836(b)(3) does provide one.”).

Motion for Summary Judgment nor alleged in its Counterclaim that MWG failed to satisfy J 7.9 of

the Agreement. Doc. [82] 4 2, 5.

After reviewing the Counterclaim, Doc. [15], the Amended Counterclaim, Doc. [31], the

Motion for Summary Judgment, Docs. [63], and the Memorandum in Support, Doc. [64], it is clear

that MWG 1s correct. ETS may not raise new grounds in its reply brief at summary judgment. See

F.T.C. v. Naswngs, 580 F.3d 769, 775 (8th Cir. 2009) (noting that “{c]laims not raised in an opening

brief are deemed waived”’) (quoting Jenkins v. Winter, 540 F.3d 742, 751 (8th Cir. 2008)); see also WireCo

WarldGraup, Inc, 231 F. Supp. 3d at 317-18 (quoting Gilmour, 382 F.3d at 1315), affd, 897 F.3d 987

(8th Cir. 2018). Therefore, the Court does not address those grounds for relief and denies MWG’s

Motion for Leave to File a Sur-Reply as moot.

Accordingly,

IT IS HEREBY ORDERED that Defendants’ Motion for Summary Judgment 1s

GRANTED as to Complaint Count IV and Complaint Counts I, III, V, and VI as they relate to

Defendants’ alleged use or disclosure of U.S. Department of Defense research.

IT ISFURTHER ORDERED that, in all other respects, Defendant’s Motion for Summary

Judgment (Doc. [63]) is DENIED.

IT IS FINALLY ORDERED that Plaintiffs Motion for Leave to File a Sur Reply (Doc.

[82]) is DENIED as moot.

The Court will issue a separate partial judgment consistent with this Memorandum and Order.

Defendants are instructed to file Exhibits N, P-1, Q-1, and R-1 on the docket within 14

days of entry of this Order.

Dated this 18" day of February, 2022.

SARAH E. PITL

UNITED STATES DISTRICT JUDGE

22